Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors

被引：0
|
作者：
Casalino, S. [1 ]
Gerdes, C. [2 ]
Saborowski, A. [2 ]
Quinzii, A. [1 ]
Zecchetto, C. [1 ]
Sordo, A. [3 ]
Messineo, L. [1 ]
Leta, L. C. [1 ]
Lucin, E. [1 ]
Mendo, L. [1 ]
Pietrobono, S. [1 ]
Vogel, A. [4 ]
Melisi, D. [1 ]
机构：
[1] Univ Verona, Digest Mol Clin Oncol Res Unit, Verona, Italy
[2] MHH, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[3] Univ Padua, Unit Biostat Epidemiol & Publ Hlth, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy
[4] Princess Margaret Canc Ctr, Div Gastroenterol & Hepatol, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.447
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
304P
引用
收藏
页码：S128 / S129
页数：2
相关论文
共 50 条
  • [11] Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management
    Chakrabarti, Sakti
    Finnes, Heidi D.
    Mahipal, Amit
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (01) : 85 - 98
  • [12] Successful intrahepatic cholangiocarcinoma conversion surgery after administration of fibroblast growth factor receptor inhibitor
    Kaneko, Junichi
    Kiuchi, Ryota
    Takinami, Masaki
    Ohnishi, Ippei
    Ito, Jun
    Jindo, Osamu
    Nishino, Masafumi
    Takahashi, Yurimi
    Yamada, Takanori
    Sakaguchi, Takanori
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (05) : 936 - 942
  • [13] Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy
    Lau, David K.
    Jenkins, Laura
    Weickhardt, Andrew
    CANCER DRUG RESISTANCE, 2019, 2 (03) : 568 - 579
  • [14] Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection
    Toshida, Katsuya
    Itoh, Shinji
    Yugawa, Kyohei
    Kosai, Yukiko
    Tomino, Takahiro
    Yoshiya, Shohei
    Nagao, Yoshihiro
    Kayashima, Hiroto
    Harada, Noboru
    Kohashi, Kenichi
    Oda, Yoshinao
    Yoshizumi, Tomoharu
    HEPATOLOGY RESEARCH, 2023, 53 (05) : 432 - 439
  • [15] Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
    Borad, Mitesh J.
    Gores, Gregory J.
    Roberts, Lewis R.
    CURRENT OPINION IN GASTROENTEROLOGY, 2015, 31 (03) : 264 - 268
  • [16] Fibroblast Growth Factor Receptor Inhibitors
    Kumar, Suneel B. V. S.
    Narasu, Lakshmi
    Gundla, Rambabu
    Dayam, Raveendra
    Sarma, J. A. R. P.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (04) : 687 - 701
  • [17] A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy
    Chauhan, Aditya
    Likasitwatanakul, Pornlada
    Ahmed, Ammar
    Sibley, Shalamar D.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [18] Role of the fibroblast growth factor receptor axis in cholangiocarcinoma
    Ang, Celina
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (07) : 1116 - 1122
  • [19] The interaction of fibroblast growth factor/fibroblast growth factor receptor and FGF inhibitors
    Fan, HK
    Zhou, H
    Li, W
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2001, 28 (03) : 338 - 341
  • [20] Durable response from fibroblast growth factor receptor inhibition in intrahepatic cholangiocarcinoma terminated by metachronous acute myeloid leukemia: a case report
    Juarso, Andreas Edwin
    Entz, Stefanie
    Weissinger, Florian
    JOURNAL OF MEDICAL CASE REPORTS, 2023, 17 (01)
12345